The role of targeted therapy in ovarian cancer

Eur J Cancer. 2011 Sep;47 Suppl 3:S116-30. doi: 10.1016/S0959-8049(11)70155-1.


Ovarian cancer is the second most common gynaecological malignancy and the leading cause of death from gynaecological cancer. Although in some cases treatment is initially effective, there is a considerable risk of disease recurrence and resistance to therapy. Therapies targeting molecular alterations in tumours offer the promise of significantly improved treatment. So far, the most promising targeted agents are angiogenesis inhibitors and PARP inhibitors. Here, we review the various targeted therapeutic approaches under clinical investigation in phase I and II trials of ovarian cancer and the challenges facing their future success in the clinic.

Publication types

  • Evaluation Study
  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Carcinoma / blood supply
  • Carcinoma / therapy*
  • Clinical Trials, Phase I as Topic / methods
  • Clinical Trials, Phase II as Topic / methods
  • Female
  • Humans
  • Models, Biological
  • Molecular Targeted Therapy / methods*
  • Molecular Targeted Therapy / statistics & numerical data
  • Ovarian Neoplasms / blood supply
  • Ovarian Neoplasms / therapy*
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors


  • Antineoplastic Agents
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A